Human Embryonic Stem Cell Differentiation Protocol
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating pluripotent stem cells into insulin-producing cells are inefficient, particularly in maintaining the expression of critical markers like PDX1 and NKX6.1 while minimizing NGN3 expression, which is essential for guiding the differentiation towards pancreatic endocrine cells, especially in human embryonic stem cells that require specific conditions different from mouse models.
Innovation Solution
A method involving culturing pluripotent stem cells to express markers characteristic of the pancreatic endoderm lineage by treating them with FGF7, noggin, a TGF-β receptor agonist, and retinoic acid, while maintaining NGN3 expression at a minimal level until differentiation into pancreatic endocrine precursor cells, ensuring co-expression of PDX1 and NKX6.1 without CDX2, to enhance the efficiency of differentiating human embryonic stem cells into insulin-producing cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional differentiation methods are used to generate insulin-producing cells from pluripotent stem cells, then cell production is achieved, but differentiation efficiency is low and critical marker expression (PDX1, NKX6.1) is not adequately maintained
Solution Approach 1:
The differentiation process is divided into distinct sequential stages: definitive endoderm formation (days 0-4), pancreatic endoderm formation (days 4-8), and pancreatic endocrine precursor formation (days 8-14). Each stage has specific growth factor conditions and duration, allowing optimized control of marker expression at each step while maintaining overall differentiation efficiency
Solution Approach 2:
The protocol establishes definitive endoderm as an intermediate stage before pancreatic endoderm formation, with preliminary expression of markers (SOX17, GATA4, HNF3beta) confirmed before proceeding. This preliminary establishment ensures proper lineage commitment and prepares cells for subsequent PDX1 and NKX6.1 expression with higher efficiency
2Ease of manufacture
If mouse embryonic stem cell models are used for differentiation, then established protocols exist, but human embryonic stem cells require different conditions reducing applicability
Solution Approach 1:
The protocol uses human-specific parameter optimizations including FGF7 concentration (50 ng/mL), retinoic acid concentration (1 μM), and specific TGF-β receptor agonist dosing tailored for human embryonic stem cells. These parameter adjustments ensure high differentiation efficiency in human cells while maintaining protocol structure that can be adapted from mouse models
3Productivity
If NGN3 expression is elevated early in differentiation, then pancreatic endocrine cell formation is promoted, but PDX1 and NKX6.1 expression is reduced compromising insulin production capability
Solution Approach 1:
NGN3 expression is controlled through periodic timing in the differentiation protocol: pancreatic endoderm is first established with PDX1 and NKX6.1 expression (days 4-8), then NGN3 is induced at the transition to endocrine precursor stage (days 8-14). This periodic induction ensures proper temporal sequence where PDX1 and NKX6.1 are maintained before NGN3 upregulation, preserving insulin production capability while forming endocrine cells
Data Source
Figure 1
Figure 2a~2f
Figure 3a~3d
AI summary
The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce cells capable of producing insulin following transplantation into an animal.